(Q24193554)

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

Differences in reactogenicity and antigenicity of acellular and standard pertussis vaccines combined with diphtheria and tetanus in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

Comparison of an acellular pertussis-component diphtheria-tetanus-pertussis (DTP) vaccine with a whole-cell pertussis-component DTP vaccine in 17- to 24-month-old children, with measurement of 69-kilodalton outer membrane protein antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

Comparison of acellular and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants. The APDT Vaccine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

Diphtheria, tetanus, and pertussis vaccine. A comparison of the immune response and adverse reactions to conventional and acellular pertussis components

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

Evaluation of a new highly purified pertussis vaccine in infants and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

Controlled study of a new five-component acellular pertussis vaccine in adults and young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

Comparison of acellular (B type) and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines as the first booster immunization in 15- to 24-month-old children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

A Controlled Trial of Two Acellular Vaccines and One Whole-Cell Vaccine against Pertussis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

Acellular pertussis diphtheria-tetanus-pertussis vaccine containing separately purified pertussis toxoid, filamentous haemagglutinin and 69 kDa outer membrane protein as a booster in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccine (dTpa) administered as a booster to 4-6 year-old children primed with four doses of whole-cell pertussis vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

Antibody response and reactions to completion of a four-dose series with a two- or three-component acellular pertussis vaccine compared to whole cell pertussis vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

Comparative safety and immunogenicity of an acellular versus whole-cell pertussis component of diphtheria-tetanus-pertussis vaccines in Senegalese infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

A placebo-controlled trial of a pertussis-toxoid vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

Study of pertussis vaccines in infants: comparison of response to acellular pertussis DTP vaccines containing 25 micrograms of FHA and either 25 or 8 micrograms of PT with response to whole-cell pertussis DTP vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 4- through 6-year-old children. Elmwood Pediatric Associates, Pennridge Pediatric Associates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

Reactogenicity and immunogenicity of a three-component acellular pertussis vaccine administered as the primary series to 2, 4 and 6 month old infants in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

Acellular pertussis vaccine: immunogenicity and safety of an acellular pertussis vs. a whole cell pertussis vaccine combined with diphtheria and tetanus toxoids as a booster in 18- to 24-month old children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

What is new in pertussis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

Control of pertussis--lessons learnt from a 10-year surveillance programme in Sweden.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

Acellular pertussis vaccine safety and efficacy in children, adolescents and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

Epidemic pertussis in 2012--the resurgence of a vaccine-preventable disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

Language bias in randomised controlled trials published in English and German.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

T- and B-cell-mediated protection induced by novel, live attenuated pertussis vaccine in mice. Cross protection against parapertussis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

Changing epidemiology and emerging risk groups for pertussis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

Impact of routine vaccination with a pertussis toxoid vaccine in Denmark.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

Safety and immunogenicity of a combined DTPa-IPV vaccine administered as a booster from 4 years of age: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

Systematic review of the effects of pertussis vaccines in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

Bordetella pertussis infection: pathogenesis, diagnosis, management, and the role of protective immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

Efficacy of a two-component acellular pertussis vaccine in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

Priming with whole-cell versus acellular pertussis vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

Assessment of publication bias for the surgeon scientist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

The immunology of bordetella pertussis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

Acellular pertussis vaccines for adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

Vaccines: correlates of vaccine-induced immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

Clinical and economic assessment of different general population strategies of pertussis vaccine booster regarding number of doses and age of application for reducing whooping cough disease burden: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

Development of a pertussis component vaccine in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

Efficacy of acellular pertussis vaccine in early childhood after household exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

Acellular pertussis vaccines in Japan: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

Acellular vaccines for preventing whooping cough in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

Acellular vaccines for preventing whooping cough in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of age

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

Nature, evolution, and appraisal of adverse events and antibody response associated with the fifth consecutive dose of a five-component acellular pertussis-based combination vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

The Effect of Changing From Whole-Cell to Acellular Pertussis Vaccine on the Epidemiology of Hospitalized Children With Pertussis in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

New Pertussis Vaccination Strategies beyond Infancy: Recommendations by the Global Pertussis Initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

Number and Order of Whole Cell Pertussis Vaccines in Infancy and Disease Protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

Comparison of acellular and whole-cell pertussis-component DTP vaccines. A multicenter double-blind study in 4- to 6-year-old children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

7 January 2021

Acellular pertussis vaccines. Efficacy and evaluation of clinical case definitions

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

7 January 2021

Safety and immunogenicity of a five-component acellular pertussis vaccine with varying antigen quantities

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

7 January 2021

Acellular vaccines for preventing whooping cough in children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

7 January 2021

Acellular vaccines for preventing whooping cough in children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

7 January 2021

Protective effect of acellular pertussis vaccines

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

7 January 2021

Phase II trial of whole-cell pertussis vaccine vs an acellular vaccine containing agglutinogens

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

7 January 2021

Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

7 January 2021

Comparative study of Lederle/Takeda acellular and Lederle whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants in Germany

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

7 January 2021

Adverse reactions and antibody response to four doses of acellular or whole cell pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

7 January 2021

Comparative study of a whole-cell pertussis vaccine and a recombinant acellular pertussis vaccine. The Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

7 January 2021

Does blinding of readers affect the results of meta-analyses? University of Pennsylvania Meta-analysis Blinding Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

7 January 2021

Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

7 January 2021

Antibody and cell-mediated immune responses to booster immunization with a new acellular pertussis vaccine in school children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

7 January 2021

A search for serologic correlates of immunity to Bordetella pertussis cough illnesses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

7 January 2021

Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

7 January 2021

A randomized controlled trial of two acellular pertussis-diphtheria-tetanus vaccines in primary immunization in Ghana: Antibody responses and adverse reactions

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

7 January 2021

Pertussis immunization with acellular vaccines in Ghanaian children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

7 January 2021

Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

7 January 2021

Vaccines for the unvaccinated: protecting the herd

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

7 January 2021

The multicenter acellular pertussis trial: an overview

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

7 January 2021

Mortality and morbidity from invasive bacterial infections during a clinical trial of acellular pertussis vaccines in Sweden.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

7 January 2021

Comparison of a three-component acellular pertussis vaccine with whole cell pertussis vaccine in two-month-old children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

7 January 2021

Acellular pertussis vaccine as a booster dose for seventeen- to nineteen-month-old children immunized with either whole cell or acellular pertussis vaccine at two, four and six months of age

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

7 January 2021

Safety and immunogenicity of Chiron/Biocine recombinant acellular pertussis-diphtheria-tetanus vaccine in infants and toddlers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

7 January 2021

Unchanged efficacy of a pertussis toxoid vaccine throughout the two years after the third vaccination of infants

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

7 January 2021

Safety and efficacy of acellular pertussis vaccine in Japan, evaluated by 23 years of its use for routine immunization

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

7 January 2021

A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

1 reference

7 January 2021

Acellular pertussis vaccine boosters combined with diphtheria and tetanus toxoid boosters for adolescents: safety and immunogenicity assessment when preceded by different 5-dose DTaP/DTwP schedules

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

7 January 2021

Metabolic and hematologic effects and immune complex formation related to pertussis immunization

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

7 January 2021

A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

7 January 2021

Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001478.PUB6

7 January 2021

10.1002/14651858.CD001478.PUB6

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

25228233

1 reference

Consolidated OpenCitations Corpus – April 2017